tylim
- Health Canada has authorized Eli Lilly’s atopic dermatitis treatment Ebglyss (lebrikizumab).
- The biologic is a first-line therapy for those 12 years and older.
- Ebglyss is given every four weeks, and trials showed that skin clearance and itch relief was seen as soon as four weeks.
- Ebglyss was approved in the European Union in November 2023. However, the U.S. FDA declined to approve it in October 2023 citing issues at a third-party manufacturing site.